New Enterprise Associates

Orbis Medicines is a company that develops a macrocyclic chemistry and computational platform for oral macrocycle drug discovery. The platform generates macrocycle candidates, nCycles, optimized for oral bioavailability to advance therapeutics that historically faced development hurdles. Its pipeline centers on nCycle candidates targeting validated biologic targets that are typically addressed by injectable drugs, with the goal of enabling oral delivery of such therapies. The platform combines chemistry and computational methods to accelerate drug discovery toward challenging targets in unmet-need indications, supporting therapeutics designed to improve patient outcomes.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Pathos develops an AI-enabled drug discovery platform aimed at reducing the medication development process. Its self-learning platform uses big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy, enabling drug developers to explore novel concepts and advance breakthrough therapies for various diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

858 Therapeutics is a biotechnology company specializing in the discovery of small molecule therapeutics for novel targets in oncology and immunology. The company focuses on innovative approaches such as synthetic lethality, innate immunity, and RNA modulation, with its lead program being a PARG inhibitor currently in early clinical development.

Cardurion Pharmaceuticals, LLC, established in 2017 and headquartered in Boston, Massachusetts, is a biotechnology company dedicated to developing innovative therapies for heart failure and other cardiovascular diseases. The company is advancing clinical programs that target PDE9 and CaMKII inhibition, utilizing its expertise in cardiovascular signaling pathways to address significant unmet patient needs.

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune and immune-mediated diseases. Based in Florida, United States, the company advances biologic programs and aims to modulate B cell–driven pathology. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb on B cells, thereby inhibiting harmful immune activity without depleting B cells.

Xaira Therapeutics is a biotechnology company that leverages artificial intelligence to revolutionize drug discovery and development. Headquartered in the San Francisco Bay Area, Xaira brings together machine learning experts, expansive data generation, and robust therapeutic product development to advance treatments for various diseases.

Avenzo Therapeutics focuses on developing innovative cancer treatments. It operates a clinical-stage platform dedicated to creating novel therapies for underserved cancers, with a pipeline targeting rare and genomically defined cancers.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. Its mission is to provide safe, effective, evidence-based, and affordable therapies for treating life-threatening complications of pregnancy.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Spyglass Pharma specializes in developing innovative treatments for chronic eye diseases using advanced technologies. The company aims to deliver multiple drugs to address additional ophthalmic indications.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Launchpad Therapeutics is an antibody-focused precision oncology company.

Escient Pharmaceuticals, Inc. is a biotechnology company based in San Diego, California, specializing in the development and manufacture of G protein-coupled receptor (GPCR)-targeted drugs aimed at treating neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, Escient focuses on harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs). The company aims to provide innovative therapies for a variety of conditions, including mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers facing these complex diseases.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, specializing in the development of peripherally-restricted CB1 receptor inverse agonists aimed at treating various metabolic and fibrotic disorders. Founded in 2015, the company focuses on creating innovative therapies for conditions such as Prader-Willi syndrome, diabetes, and complications related to obesity. Its pipeline includes treatments for diabetic kidney disease, non-alcoholic steatohepatitis, and progressive fibrosis, including interstitial lung disease. Inversago Pharma aims to improve patient outcomes by offering new therapeutic options that target the underlying mechanisms of these diseases.

Allakos is a clinical-stage biopharmaceutical company developing antibody-based therapeutics targeting immunomodulatory receptors on immune effector cells. Its pipeline focuses on allergic, inflammatory, and proliferative diseases, with lead programs targeting Siglec-6 (AK006) and Siglec-8.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

X4 Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel oral small molecule therapeutics targeting chemokine receptor CXCR4. Its lead drug candidate, mavorixafor (X4P-001), is in Phase III trials for the treatment of WHIM syndrome and has shown promising results in other indications such as severe congenital neutropenia and clear cell renal cell carcinoma.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Celcuity is a clinical-stage biotechnology company that discovers new cancer sub-types and therapeutic options using its proprietary CELsignia diagnostic platform. This platform analyzes living tumor cells to identify specific abnormal cellular processes driving cancer, enabling the development of targeted therapies for patients.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Waymark is a healthcare company focused on improving access to and quality of care for Medicaid beneficiaries. It delivers community-based services and collaborates with primary care providers to enhance access and health outcomes for patients enrolled in Medicaid. The company provides health plans, insulin education, and training, and creates employment opportunities for community-based care teams, supporting coordinated care and patient engagement so beneficiaries can monitor and manage their health.

Founded in 2020 and headquartered in San Diego, California, Sorriso Pharmaceuticals is a biotechnology company dedicated to developing disease-modifying antibodies for treating inflammatory diseases such as Crohn's disease and ulcerative colitis. Its proprietary platform generates potent antibodies designed for oral delivery, aiming to maintain therapeutic activity throughout the intestinal system.

InCarey is a Shanghai-based company founded in 2011 that specializes in developing a comprehensive medical service platform focused on the management of chronic and vertical diseases. The platform integrates medical, pharmaceutical, and insurance resources to provide a one-stop solution for patients requiring long-term care and support. InCarey's cloud-based online platform facilitates professional disease management services, allowing for direct interaction between doctors and patients. Additionally, it includes an e-commerce component that enables users to conveniently access medications for various chronic conditions. The company is dedicated to enhancing the patient experience through innovative payment services and a holistic approach to chronic disease management.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Recludix Pharma develops a platform for discovering potent and selective inhibitors of complex protein targets. The platform integrates custom-generated DNA-encoded libraries, massively parallel structure-activity relationship determination, and proprietary screening tools to ensure selectivity.

858 Therapeutics is a biotechnology company specializing in the discovery of small molecule therapeutics for novel targets in oncology and immunology. The company focuses on innovative approaches such as synthetic lethality, innate immunity, and RNA modulation, with its lead program being a PARG inhibitor currently in early clinical development.

Allay Therapeutics is pioneering ultra-sustained pain therapeutics to transform post-surgical pain management. Its proprietary platform combines non-opioid analgesics and biopolymers to create dissolvable therapeutics delivering pain relief within targeted sites over weeks, significantly longer than current treatments. The company's lead product candidate, ATX101, is in Phase 2 clinical trials for total knee replacement surgeries.

Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine. The company's lead product candidate, STS101, is a drug-device combination that incorporates a proprietary dry-powder formulation of dihydroergotamine mesylate. Designed for self-administration, STS101 utilizes a pre-filled, single-use nasal delivery device, enhancing patient convenience and accessibility. The product is currently undergoing Phase III clinical trials, marking a significant step in its development. Founded in 2016, Satsuma is headquartered in South San Francisco, California.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Geron Corporation is a late-stage clinical biopharmaceutical company based in Menlo Park, California, specializing in the development and commercialization of therapeutics for hematologic malignancies. Established in 1990, the company is primarily focused on its investigational drug, imetelstat, a first-in-class telomerase inhibitor currently undergoing Phase 2/3 clinical trials. Imetelstat targets the uncontrolled proliferation of malignant progenitor cells, aiming to improve blood cell production in patients with conditions such as myelodysplastic syndromes and myelofibrosis. Geron generates revenue through collaboration agreements, milestones, royalties, and licensing arrangements, positioning itself as a key player in oncology therapeutics.

Arcellx is a clinical-stage biotechnology company developing immunotherapies and cell therapies for cancer and other serious diseases. It seeks to make cell therapies safer, more effective, and more broadly accessible. Its lead candidate CART-ddBCMA is in a Phase 1 trial for relapsed or refractory multiple myeloma and has FDA Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is also advancing ARC-SparX, a dosable and controllable CAR-T platform, into clinical programs ACLX-001 for relapsed or refractory multiple myeloma and ACLX-002 for relapsed or refractory acute myeloid leukemia. Arcellx's pipeline covers multiple myeloma, acute myeloid leukemia, and other cancer indications, with research extending into additional oncology areas and other serious diseases.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies aimed at addressing significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company has established a robust pipeline supported by a proprietary discovery engine and a wholly-owned research and development facility. It possesses an extensive library of molecules and a team with considerable expertise in developing compounds that target nuclear receptors, transcription factors, and epigenetic modulation. Inventiva is advancing clinical candidates, including lanifibranor, which is being developed for non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. Additionally, the company is engaged in a variety of pre-clinical therapy programs, further strengthening its portfolio in the fields of oncology, fibrosis, and rare diseases.

Nkarta Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company aims to harness the inherent power of NK cells to target and destroy tumor cells, offering a potent and better-tolerated alternative to traditional T-cell therapies for a broad range of cancer indications.

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat diseases like nonalcoholic steatohepatitis (NASH) and certain cancers. The company specializes in targeting dysfunctional metabolic pathways, with a particular expertise in fatty acid synthase (FASN) biology.

Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.

Reneo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in San Diego, California, dedicated to developing therapies for patients with rare genetic mitochondrial diseases. These conditions are characterized by deficits in cellular metabolism and energy production, often leading to significant health challenges. The company is focused on creating treatments that improve mitochondrial function, preserve muscle integrity, and enhance the overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes critical to the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. Founded in 2014, Reneo aims to address the unmet needs of patients suffering from orphan metabolic diseases linked to mitochondrial dysfunction.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Polyneuron Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapeutics for the treatment of autoimmune disorders. Founded in 2014, the company specializes in creating drugs to target specific autoimmune conditions, including PN-1007 for anti-MAG neuropathy, PN-1018 for multifocal motor neuropathy, and PN-032 and PN-056 for ABO-incompatible transplantation. Polyneuron's therapeutic approach employs biodegradable glycopolymers that selectively eliminate pathological autoantibodies, preserving the overall integrity of the immune system. This technology, referred to as Antibody-Catch, aims to provide safe and effective treatment options for patients suffering from autoimmune diseases affecting the peripheral nervous system, particularly those involving autoantibodies against carbohydrate epitopes.

Imara, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapeutics for patients with rare genetic disorders of hemoglobin. Founded in 2016, the company is advancing IMR-687, an oral, once-daily therapeutic designed to treat sickle cell disease and beta-thalassemia. IMR-687 is a highly selective small molecule inhibitor of PDE9, engineered to have a multimodal mechanism of action that impacts various cell types, including red blood cells and white blood cells, as well as adhesion mediators. Through its innovative approach, Imara aims to provide disease-modifying treatments for individuals affected by hemoglobinopathies.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Curzion Pharmaceuticals is a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

CPS is a leading provider of hospital solutions, specializing in transforming operations to enhance patient care. They deliver expert services including pharmacy management, rehabilitation support, supply chain optimization, and material management to healthcare organizations.

Allay Therapeutics is pioneering ultra-sustained pain therapeutics to transform post-surgical pain management. Its proprietary platform combines non-opioid analgesics and biopolymers to create dissolvable therapeutics delivering pain relief within targeted sites over weeks, significantly longer than current treatments. The company's lead product candidate, ATX101, is in Phase 2 clinical trials for total knee replacement surgeries.

Xenon Pharmaceuticals is a biopharmaceutical company dedicated to developing novel medicines for neurological disorders. It focuses on rare genetic defects as drug targets, leveraging its proprietary discovery platform called Extreme Genetics. The company's pipeline includes XEN1101 and XEN496 for epilepsy treatment.

Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for debilitating liver diseases. Its primary focus is on Maralixibat, an investigational oral drug in Phase 3 trials for treating progressive familial intrahepatic cholestasis disease and Alagille syndrome.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, intended to manage uncontrolled bleeding events or urgent surgeries. PhaseBio is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

CareZone is a healthcare platform focused on simplifying personal healthcare management and enhancing coordination among family members and caregivers. The company offers a solution that automates prescription refill reminders, appointment tracking, and provides controlled access to health information, allowing users to manage their healthcare needs efficiently. By centralizing these services in a single interface, CareZone enables individuals to better organize their health management and facilitate communication with those involved in their care.

MEI Pharma is a biopharmaceutical company focused on developing novel therapies for cancer. Its pipeline includes Zandelisib (PI3K inhibitor) and Voruciclib (CDK9 inhibitor), both in clinical trials, as well as Pracinostat (HDAC inhibitor). The company collaborates with other pharmaceutical companies for drug development.

Collective Health provides a cloud-based health benefits platform that unifies medical, dental, vision, pharmacy, and related programs into a single administration experience, helping employers simplify benefits, guide employees in understanding and navigating care, and manage costs and outcomes. The platform offers integrated administration of all health plans through one portal, with live concierge support and digital tools to find and manage care, and connects employees with medical, pharmacy, dental, and vision providers. Headquartered in San Francisco with offices in Chicago and Lehi, it aims to reduce the administrative burden of delivering benefits while improving member experience and overall health outcomes.

Senti Biosciences is a biotechnology company focused on synthetic biology. It develops gene circuit platforms to engineer therapeutics, with a focus on improving precision and control in cancer treatments.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Xoc Pharmaceuticals, Inc. is a biotechnology company based in Los Gatos, California, that focuses on developing innovative therapeutics for neurology and related therapeutic areas. Incorporated in 2013, the company employs advanced receptor characterization technology and cutting-edge medicinal chemistry to identify and develop novel oral therapies aimed at preventing migraines and managing Parkinson's disease. Xoc Pharmaceuticals emphasizes improved safety and efficacy in its treatments, utilizing a development strategy that incorporates targeted molecular modifications and optimized delivery routes. By leveraging the pharmacological history of compounds similar to its product candidates, the company effectively manages clinical and regulatory risks associated with its development programs, ultimately striving to enhance patient outcomes for those with neurological disorders.

CTI BioPharma Corp. is a biopharmaceutical company headquartered in Seattle, Washington, that specializes in the acquisition, development, and commercialization of targeted therapies for blood-related cancers. Founded in 1991 and formerly known as Cell Therapeutics, Inc., the company is primarily focused on developing novel treatments to improve patient outcomes in oncology. Its key investigational product, pacritinib, is an oral kinase inhibitor currently in Phase III clinical trials for the treatment of myelofibrosis in adults. In addition to pacritinib, CTI BioPharma's portfolio includes other candidates like Pixantrone, which is undergoing Phase III trials for non-Hodgkin's lymphoma, and Brostallicin, currently in a Phase II study for sarcoma. The company has established collaboration and licensing agreements with several pharmaceutical partners.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Centrexion Therapeutics is a late-stage biopharmaceutical company dedicated to developing non-opioid, non-addictive therapies for chronic pain management. Its pipeline includes CNTX-4975 in Phase III trials for knee osteoarthritis pain, and other candidates in various stages of clinical development targeting diverse pain conditions.

Allakos is a clinical-stage biopharmaceutical company developing antibody-based therapeutics targeting immunomodulatory receptors on immune effector cells. Its pipeline focuses on allergic, inflammatory, and proliferative diseases, with lead programs targeting Siglec-6 (AK006) and Siglec-8.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Inozyme Pharma, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases related to abnormal mineralization affecting the vasculature, soft tissue, and skeletal systems. The company's lead product candidate, INZ-701, is a recombinant protein designed to treat rare genetic conditions caused by ENPP1 and ABCC6 deficiencies, as well as calciphylaxis. Inozyme's therapies aim to address the underlying causes of these debilitating diseases, providing potentially disease-modifying treatments for conditions such as Generalized Arterial Calcification of Infancy and Autosomal Recessive Hypophosphatemic Rickets Type 2. The company has a licensing agreement with Yale University for certain therapeutic applications and is headquartered in Boston, Massachusetts. Established in 2015, Inozyme is dedicated to improving the quality of life for patients affected by severe metabolic disorders associated with mineral imbalances.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Cydan is an orphan drug accelerator focused on developing therapies for patients with rare genetic diseases. The company identifies and de-risks compounds that hold therapeutic and commercial potential, employing a rigorous process to generate data that supports both development pathways and the formation of new companies. With a team that boasts deep expertise in drug development and strong relationships within academia and patient advocacy, Cydan accelerates therapies through various stages, including clinical, regulatory, and commercial development. By facilitating the creation of effective treatments, Cydan aims to improve the lives of patients and families affected by rare diseases.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions affecting women. Its key products in development include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and heavy menstrual bleeding associated with uterine fibroids. ObsEva is also working on OBE022, a once-daily oral prostaglandin F2α receptor antagonist designed for managing preterm labor between 24 and 34 weeks of gestation, and Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily within the Swiss market while targeting global solutions for women's reproductive health needs.

Amplyx Pharmaceuticals, Inc. is a small molecule drug development company focused on creating innovative therapies for debilitating and life-threatening diseases, particularly those affecting individuals with compromised immune systems. Founded in 2006 and based in San Diego, California, the company specializes in the development of oral and injectable anti-infective drugs, including antifungal agents designed to treat invasive fungal infections caused by pathogens such as Candida and Aspergillus. Amplyx employs a unique platform approach that enhances the efficacy and reduces the toxicity of existing drugs by incorporating a second small molecule. This strategy aims to provide effective treatment options for patients undergoing chemotherapy and other immunosuppressive therapies, ensuring they receive appropriate care both during hospitalization and after discharge.

Complexa, Inc. is a biopharmaceutical company focused on developing innovative medicines for severe and life-threatening conditions related to fibrosis and inflammation. Founded in 2008 and based in Berwyn, Pennsylvania, the company specializes in researching endogenous human cell signaling technologies to address a range of inflammatory, fibrotic, and central nervous system diseases. Its proprietary technology centers on the synthesis and therapeutic use of endogenous nitro-fatty acids, which serve as cell-signaling agents that modulate key inflammatory pathways. Notable among its developments is CXA-10, an oral nitrated fatty acid compound aimed at treating conditions such as focal segmental glomerulosclerosis and pulmonary arterial hypertension. Through its research efforts, Complexa aims to enhance existing anti-inflammatory and metabolic signaling mechanisms to support the resolution and repair of both acute and chronic tissue injuries.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

Nightstar Therapeutics is a clinical-stage gene therapy company based in London, United Kingdom, specializing in the development of innovative one-time treatments for rare inherited retinal diseases. The company is advancing several product candidates, including its lead candidate NSR-REP1, which is in phase 3 clinical development for choroideremia. Additionally, Nightstar is working on NSR-RPGR, currently in phase 2/3 trials for X-linked retinitis pigmentosa, as well as NSR-BEST1. The company is also developing NSR-ABCA4, which is in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address significant unmet medical needs in the field of retinal disorders.

Aera Technology is a decision intelligence company that provides a cloud platform, Aera Decision Cloud, to integrate with existing systems and data sources and enable real-time decision making at scale across enterprise operations. The platform supports cognitive automation, data modeling, artificial intelligence, and machine learning, and lets organizations automate processes and build digital skills that connect disparate data sources. It is used for functions such as demand planning in supply chains by harmonizing data from ERP, CRM, sales, marketing, trends, and social feeds. The company serves pharma, manufacturing, retail, wholesale, and consumer packaged goods. Founded in 1999 and headquartered in Mountain View, California, Aera Technology operates globally.

OrphoMed, Inc. is a San Francisco-based pharmaceutical company that specializes in developing novel therapies for conditions such as irritable bowel syndrome with diarrhea (IBS-D), acute and chronic pain, and cystic fibrosis. Established in 2015, the company utilizes its proprietary DIMERx™ platform technology to create first-in-class therapeutic dimer conjugates aimed at addressing visceral hypersensitivity and pancreatitis. Among its key pipeline candidates is ORP-101, a peripherally acting sodium ion channel blocker that acts as a μ agonist and κ antagonist, designed to minimize abuse potential and reduce risks associated with pancreatitis. OrphoMed is also working on ORP-105, a non-addictive, centrally-acting analgesic, and ORP-110, a potentiator for cystic fibrosis treatment. The company's innovative approach not only aims to reshape pain management but also seeks to fulfill unmet medical needs across various gastrointestinal and pain-related disorders, leveraging the safety and efficacy of its compounds, which have proven track records for other indications.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing oral small-molecule drugs that act as allosteric modulators of central nervous system targets, especially G-protein coupled receptors. Based in Geneva, Switzerland, the company aims to address CNS disorders with a platform that may offer advantages over conventional orthosteric therapies. Its lead programs include Dipraglurant for Parkinson's disease levodopa-induced dyskinesia and dystonia, ADX71149 for epilepsy and other CNS conditions, and a GABAB positive allosteric modulator for addiction. It collaborates with Janssen Pharmaceuticals to develop mGluR2 PAM compounds. Founded in 2002, Addex operates in Switzerland and Europe, pursuing discovery, development, and potential commercialization of small-molecule therapeutics for CNS disorders.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for treating rare genetic disorders that cause life-threatening metabolic issues. Its lead product candidate, setmelanotide, is a potent melanocortin-4 receptor agonist designed for precision medicine to treat hyperphagia and severe obesity resulting from rare MC4R pathway diseases.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-targeted therapies for various diseases. Founded in 2007 and headquartered in San Diego, California, the company focuses on innovative treatments for conditions such as kidney diseases and viral infections. Its lead product candidates include RG-012, an anti-miR targeting miR-21, currently in Phase II clinical trials for Alport syndrome, and RGLS4326, an anti-miR targeting miR-17, which is undergoing Phase Ib clinical trials for autosomal dominant polycystic kidney disease. Additionally, Regulus is advancing a pipeline of preclinical drug candidates, including RGLS5579 to inhibit miR-10b, as well as programs aimed at treating Hepatitis B virus and Non-Alcoholic Steatohepatitis. The company's work leverages the recent scientific advancements in microRNA research, which play a crucial role in regulating gene expression.

Immunomedics, Inc. is a clinical-stage biopharmaceutical company based in Morris Plains, New Jersey, that specializes in developing monoclonal antibody-based products for the targeted treatment of cancer. The company is primarily focused on sacituzumab govitecan, an antibody-drug conjugate designed for patients with metastatic triple-negative breast cancer, aiming to position it as a third-line therapy in the United States. Additionally, Immunomedics is engaged in the development of other product candidates, including IMMU-140 for hematologic malignancies and IMMU-130 for colorectal cancer. The company has established clinical collaborations with major pharmaceutical entities to enhance its research and treatment capabilities. Founded in 1982, Immunomedics operates with the goal of delivering innovative therapies to patients with serious diseases. As of October 2020, it functions as a subsidiary of Gilead Sciences, Inc.